Status:
COMPLETED
UK Study Assessing Flexible Dose Fesoterodine in Adults
Lead Sponsor:
Pfizer
Conditions:
Urinary Bladder, Overactive
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To explore the effects of fesoterodine when used in a flexible dose manner
Eligibility Criteria
Inclusion
- Male or female \>18 years old
- OAB for \>3 months
Exclusion
- Patients with conditions that would contraindicate for fesoterodine use
- Patients with significant hepatic and renal disease or other significant unstable diseases.
- OAB symptoms caused by neurological conditions, known pathologies of urinary tract, etc.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
331 Patients enrolled
Trial Details
Trial ID
NCT00806494
Start Date
February 1 2009
End Date
January 1 2010
Last Update
January 26 2011
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Ely, Cambridgeshire, United Kingdom, CB7 5JD
2
Pfizer Investigational Site
Crewe, Cheshire, United Kingdom, CW1 4QJ
3
Pfizer Investigational Site
Fowey, Cornwall, United Kingdom, PL23 1DT
4
Pfizer Investigational Site
Penzance, Cornwall, United Kingdom, TR18 4JH